SAVA, GIANNI
 Distribuzione geografica
Continente #
NA - Nord America 17.992
EU - Europa 9.300
AS - Asia 1.374
SA - Sud America 42
Continente sconosciuto - Info sul continente non disponibili 30
AF - Africa 11
OC - Oceania 11
Totale 28.760
Nazione #
US - Stati Uniti d'America 17.948
UA - Ucraina 1.928
SE - Svezia 1.887
DE - Germania 1.132
PL - Polonia 1.120
IT - Italia 931
CN - Cina 881
FI - Finlandia 577
GB - Regno Unito 463
TR - Turchia 342
BG - Bulgaria 305
RU - Federazione Russa 294
IE - Irlanda 293
FR - Francia 145
BE - Belgio 56
CH - Svizzera 53
CA - Canada 33
EU - Europa 30
IN - India 28
SG - Singapore 21
BR - Brasile 19
NL - Olanda 18
VN - Vietnam 18
RO - Romania 17
CZ - Repubblica Ceca 13
SA - Arabia Saudita 12
PT - Portogallo 11
TH - Thailandia 11
AT - Austria 10
CL - Cile 10
RS - Serbia 10
ID - Indonesia 9
HK - Hong Kong 8
KR - Corea 8
DK - Danimarca 7
MX - Messico 7
MY - Malesia 7
AU - Australia 6
EG - Egitto 6
GR - Grecia 6
HR - Croazia 6
IR - Iran 6
AR - Argentina 5
ES - Italia 5
HU - Ungheria 5
JP - Giappone 5
NZ - Nuova Zelanda 5
GE - Georgia 4
VE - Venezuela 3
BO - Bolivia 2
CO - Colombia 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
MD - Moldavia 2
PK - Pakistan 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GT - Guatemala 1
HN - Honduras 1
JO - Giordania 1
KE - Kenya 1
LU - Lussemburgo 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
SI - Slovenia 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 28.760
Città #
Woodbridge 2.486
Ann Arbor 2.405
Fairfield 1.905
Houston 1.682
Jacksonville 1.663
Chandler 1.277
Wilmington 1.108
Warsaw 1.104
Ashburn 903
Seattle 790
Cambridge 647
Princeton 582
Sofia 305
Dublin 290
Beijing 286
Izmir 281
Dearborn 217
Boardman 187
Trieste 154
San Diego 138
Milan 109
Düsseldorf 81
Chicago 67
Hefei 61
Falls Church 55
Brussels 54
Verona 53
Kocaeli 51
Norwalk 48
Redwood City 48
Kunming 44
Bern 43
Buffalo 42
Bremen 41
Nanjing 40
Mestre 39
Phoenix 34
Des Moines 32
Jinan 32
Guangzhou 30
Columbus 22
Helsinki 21
Andover 19
Fuzhou 17
Shanghai 17
Nanchang 16
Auburn Hills 15
Ottawa 15
Redmond 15
Shenyang 15
Dong Ket 14
Hebei 14
Hangzhou 13
Zhengzhou 13
Fremont 11
New York 11
Chengdu 10
Mountain View 10
Brno 9
Poplar 9
Chongqing 8
Indiana 8
Vienna 8
Baotou 7
Changsha 7
Costa Mesa 7
Dallas 7
Grafing 7
North Bergen 7
Wuhan 7
Xian 7
Boydton 6
Chaoyang 6
Chennai 6
Hanover 6
Lisbon 6
London 6
Polska 6
Riyadh 6
São Paulo 6
Tappahannock 6
Tianjin 6
Washington 6
Wenzhou 6
Al Kharj 5
Athens 5
Atlanta 5
Jiaxing 5
Los Angeles 5
Munich 5
Nanning 5
Padova 5
Palermo 5
Paris 5
San Francisco 5
Scuola 5
Taiyuan 5
Torre Del Greco 5
Al Mansurah 4
Amsterdam 4
Totale 19.936
Nome #
Effects of Two Fullerene Derivatives on Monocytes and Macrophages 390
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 295
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 286
Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from Mytilus galloprovincialis 272
Chemical and Molecular Approach to Tumor Metastases 264
The differential distribution of RAPTA-T in non-invasive and invasive breast cancer cells correlates with its anti-invasive and anti-metastatic effects 229
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 202
A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival 201
New salts of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents. 190
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 180
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure 169
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 164
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 163
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. 160
Tumor inhibition and effects on host survival time by rutheniumIII andrhodiumIII complexes with dimethylsulphoxide ligands. 156
Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide 156
Ruthenium(III) complexes as antineoplastic agents. 154
Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)(Im)]. 153
A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results 152
Hydrophilic polymer coated monodispersed Fe3O4 nanostructures and their cytotoxicity 150
Investigation on the oxidative N-demethylation of aryltriazenes in vitro 149
Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review 148
Complessi trans di rutenio come agenti antineoplastici 147
Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma. 146
Effects of lysozyme on spleen and lungs in mice with Lewis lung carcinoma 146
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 142
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 141
Na[trans-RuCl4(DMSO)(Im)]*2DMSO - antimetastatic ruthenium agent 141
trans-Ru(II)dimethylsulfoxides: antineoplastic action on mouse tumors 141
Antiinflammatory action of hydrosoluble dimethyltriazenes on the carrageenin-induced edema in guinea pigs 141
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 140
Effects of trans-RuCl2 (DMSO)4 on B16 melanoma in mice. 140
Antitumor action of mer-trichlorobis(dimethyl sulfoxide)aminoruthenium(III) (BBR2382) in mice bearing Lewis lung carcinoma 140
Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. 140
Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichloro-diamminoplatinum(II) in mice bearing Lewis lung carcinoma 139
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 139
Biochemical and biological characteristics of leucocyte proteinase inhibitors. 138
Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties 138
Human recombinant lysozyme downregulates advanced glycan endproduct-induced interleukin-6 production and release in an in vitro model of human proximal tubular epithelial cells 138
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 138
Pharmacological aspects and therapeutic applications of lysozymes 137
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 136
Ruthenium complexes can target determinants of tumour malignancy 135
Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice 134
Effects of endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride 133
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model 133
The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes 132
Antitumor properties of ruthenium(II)-dimethylsulfoxide complexes in the Lewis lung carcinoma system 131
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 130
Antimetastatic action of the prostacyclin analog Iloprost in the mouse 130
null 130
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 130
Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion. 129
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy 129
Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA 129
Methodologic problems encountered in the assay of proteinases in Lewis lung carcinoma, a mouse metastasizing tumor. 128
Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme 128
Lysozyme induced recovery of the response to ConA on mononuclear cells harvested from mice bearing MCa mammary carcinoma 128
Evidence for host-mediated antitumor effects of lysozyme in mice bearing MCa mammary carcinoma 128
Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in Procambarus clarkii 128
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 127
Rhodium(III) analogs of antitumor active ruthenium(III) compounds. The crystal structure of [ImH][trans-RhCl4(Im)2] (Im = imidazole) 127
Antimetastatic effects of N-diazoacetyl-glycine derivatives in C57BL mice. 127
Tumour metastatic potential after treatment with selective antimetastatic drugs 127
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms 127
Neutral proteinase inhibitors and antimetastatic effects in mice. 126
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 126
Free exchange across cells,and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A(imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate)ON KB Tumor cells. 125
Mechanism of the antimetastatic action of N-diazoacetylglycinamide in mice bearing Lewis lung carcinoma. 125
Antimetastatic effects and tumor proteinase inhibition by spleen intracellular inhibitors of neutral proteinases. 125
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 125
Effects of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. 125
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition 124
Antileukemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukemia and on P388/DDP subline 123
Ruthenium-sulfoxide complexes with a specific antimetastatic activity 122
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq 122
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 121
Microencapsulation of Bioactive Principles with an Airless Spray-Gun Suitable for Processing High Viscous Solutions 121
Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice. 120
Cis- and trans-dihalotetrakis(dimethylsulfoxide)Ruthenium(II) Complexes (RuX2(Me2SO)4; X = Cl, Br): Synthesis, Structure and Antitumor Activity 119
Recovery of lymphocyte CD4+:CD8+ ratio in patients treated with lysozyme 119
Synthesis and characterization of a diruthenium(II,III)-ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives 119
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy 119
Metal complexes of platinum group: the promising antitumor features of cis-dichlorotetrakis(dimethylsulfoxide)Ru(II) (cis- RuCl2(DMSO)4) and related complexes 118
Effects of isomeric aryldimethyl-triazenes on Lewis lung carcinoma growth and metastases in mice 118
Antineoplastic effects of mer-RuCl3(DMSO)2(NH3) against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]. 117
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion 117
Mechanism of tumor inhibition by the metal complex trans-RuCl2(dimethylsulphoxide)4 117
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours 117
Complessi di Rutenio con elevata attività antitumorale 116
Study of a potential drug delivery system based on carbon nanoparticles: Effects of fullerene derivatives in MCF7 mammary carcinoma cells 116
Metal-based antitumour drugs in the post genomic era 115
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 115
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 115
Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. 115
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound 114
Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo 113
Malignancy and tumor proteinases: effects of proteinase inhibitors 113
Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in theLewis lung carcinoma system. 112
Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice 112
Totale 14.337
Categoria #
all - tutte 62.094
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.094


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.449 0 0 0 0 0 47 29 248 41 318 1.206 560
2019/20206.106 317 254 277 1.048 402 829 636 813 535 346 501 148
2020/20214.262 431 164 385 634 274 505 200 385 202 494 137 451
2021/20223.269 103 257 189 471 49 259 137 118 390 347 203 746
2022/20233.957 430 436 288 491 447 748 21 358 481 28 160 69
2023/2024803 170 136 117 117 227 36 0 0 0 0 0 0
Totale 29.468